Id: acc1658
Group: 2sens
Protein: beta-catenin
Gene Symbol: CTNNB1
Protein Id: P35222
Protein Name: CTNB1_HUMAN
PTM: phosphorylation
Site: Ser552
Site Sequence: AHQDTQRRTSMGGTQQQFVEG
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype:
Disease Cellline: H3255
Disease Info:
Drug: rifabutin
Drug Info: "Rifabutin is a rifamycin-class antibiotic that inhibits bacterial DNA-dependent RNA polymerase, primarily used in the treatment of tuberculosis and Mycobacterium avium complex (MAC) infections, particularly in HIV patients, with demonstrated activity against some rifampicin-resistant strains."
Effect: modulate
Effect Info: "Rifabutin inhibits eIF4E phosphorylation, reduces beta-catenin phosphorylation and its transcriptional activity, inhibits proliferation, and induces apoptosis."
Note:
Score: 4.0
Pubmed(PMID): 26944016
Sentence Index:
Sentence:

Sequence & Structure:

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Withdrawn colorectal adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Recruiting cirrhosis of liver ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed chronic myelogenous leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Terminated neoplasm ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic carcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed Malignant Pancreatic Neoplasm ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
CTNNB1-Ser552
Cancer Intensity
BRCA -1.793
COAD -0.07
HGSC 0.724
ccRCC 1.879
GBM -0.666
HNSC 0.383
LUAD 0.034
LUSC
non_ccRCC
PDAC -0.172
UCEC -0.318

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 552 D Hepatocellular carcinoma Phosphorylation 37573318
S 552 D Lung cancer Phosphorylation 30918250
S 552 U Clear cell kidney cancer Phosphorylation 34657130
S 552 U Colitis Phosphorylation 20580720
S 552 U Colorectal cancer Phosphorylation 35059735
S 552 U Non-functioning pituitary tumours Phosphorylation 36114575
S 552 U Osteoarthritis Phosphorylation 36439631
S 552 U Cholangiocarcinoma Phosphorylation 36928362
S 552 U Glioblastoma Phosphorylation 36435833

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: